About Us
Anagram Therapeutics was founded with the hope and determination to meaningfully improve the lives of people and families affected by rare diseases. We are developing targeted, orally delivered enzyme replacement therapies that seek to improve outcomes, reduce the high treatment burden, and deliver improved safety and tolerability.
Anagram is a clinical-stage biopharmaceutical company developing novel, orally delivered enzyme therapeutics for the treatment of diseases caused by malabsorption syndromes and nutrient metabolism disorders — enzyme deficiencies or genetic mutations that prevent the body from properly metabolizing or absorbing certain fats, sugars, proteins, vitamins, or other key nutrients. These conditions affect infants, children, and adults with congenital diseases worldwide, as well as others who might develop them as part of another illness.
Unfortunately, most of these life-threatening diseases are not properly treated — or have no treatment at all.
Anagram Therapeutics is committed to changing that.
